Clinical Trials


Romark is among the many companies working to respond to the novel coronavirus global health emergency. See below for additional information.

To get involved, email: or call

Romark is initiating clinical studies of its investigational medicine, NT-300 (nitazoxanide extended-release), for the prevention of COVID-19 and other viral respiratory illnesses. NT-300 is being investigated as a broad-spectrum antiviral medicine for treating and preventing viral respiratory illnesses caused by seasonal, emerging and drug-resistant viruses, including COVID-19.

NT 300 is an investigational new drug product and has not been approved by the U.S. Food and Drug Administration or other
regulatory authorities for any use. The safety and efficacy of this new product has not been established.